Ginkgo's biofoundry, which it also refers to as its cellular engineering-services segment, has one very complex, high-level goal. That goal is to provide a platform that biotech and pharma companies ...

Ginkgo Bioworks (NYSE:DNA) said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture of its biosecurity business and reporting lower year-over-year cash burn in ...

For the fourth quarter of 2025, Ginkgo Bioworks reported a strategic pivot towards robotics and AI, with CEO Jason Kelly emphasizing the company’s collaboration with the Department of Energy and ...

Detailed price information for Ginkgo Bioworks Hldgs Inc (DNA-N) from The Globe and Mail including charting and trades.

Good evening. I'm Daniel Marshall, Senior Manager of Communications and Ownership. I'm joined by Jason Kelly, our Co-Founder and CEO; and Steve Coen, our CFO. Thanks, as always, for joining us. We're ...

Thanks to its promises of low-cost bioengineering and biomanufacturing services, Ginkgo Bioworks (NYSE: DNA) could one day be the kind of biotech that everyone else in the biopharma sector wants to ...